<DOC>
	<DOCNO>NCT01706198</DOCNO>
	<brief_summary>This study design compare effectiveness safety Fluticasone Furoate/Vilanterol Inhalation Powder ( 100mcg Fluticasone Furoate ( ( FF ) , GW685698 ) /25mcg Vilanterol ( ( VI ) , GW642444 ) 200mcg Fluticasone Furoate ( ( FF ) , GW685698 ) /25mcg Vilanterol ( ( VI ) , GW642444 ) ) deliver daily via Novel Dry Powder Inhaler ( NDPI ) compare exist asthma maintenance therapy twelve month subject diagnose asthma . This Phase III multi-centre , randomise open label study . Subjects meet eligibility criterion randomise enter 12 month treatment period .</brief_summary>
	<brief_title>An Effectiveness Study Comparing Fluticasone Furoate ( FF , GW685698 ) /Vilanterol ( VI , GW642444 ) With Standard Treatment Asthma</brief_title>
	<detailed_description>This Phase III multi-centre , randomise open label study perform subject follow primary care diagnosis receive regular treatment asthma localise geographical region UK</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects eligible enrolment study must meet following criterion : 1 . Informed consent : Subjects must able provide inform consent , consent sign date . 2 . Type subject : Subjects document GP diagnosis asthma primary respiratory disease . 3 . Current AntiAsthma Therapy : All subject must prescribe maintenance therapy receive ICS without LABA ( either fix combination via separate inhaler ) , least 4 week prior Visit 2 . Other background asthma medication antileukotrienes permit 4 . All subject ICS monotherapy ICS/LABA combination ( fix dose combination ICS alone LABA alone separate inhaler ) must symptoms past week prior Visit 2 . Symptoms define daytime symptoms twice per week , use shortacting beta2agonist bronchodilator twice per week , limitation activity , nocturnal symptoms/awakening . ( The symptom base subject 's recall consistent GINA principal BTS/SIGN guideline ) . 5 . Subject questionnaire : Subjects must able complete electronic subject questionnaire well questionnaire complete phone provide proxy e.g . partner/relative/a friend behalf 6 . Gender Age : Male female subject age ≥18 year age Visit 1 . A female eligible enter participate study : Nonchild bear potential ( i.e . physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g . age appropriate , history vasomotor symptom . However questionable case , blood sample FSH &gt; 40MIU/ml estradiol &lt; 40pg/ml ( &lt; 147 pmol/L ) confirmatory . OR Child bear potential negative urine pregnancy test Visit 2 , agree one highly effective acceptable contraceptive method use consistently correctly ( i.e . accordance approve product label instruction physician duration study Visit 2 end study ) . Subjects meet follow criterion must enrol study : 1 . Recent history Lifethreatening asthma : Defined protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure within last 6 month . 2 . COPD Respiratory Disease : A subject must current evidence GP diagnosis chronic obstructive pulmonary disease . 3 . Other diseases/abnormalities : Subjects historical current evidence uncontrolled clinically significant disease . Significant define disease , opinion GP/ Investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . 4 . Drug/food allergy : Subjects history hypersensitivity study medication ( e.g. , beta2agonists , corticosteroid ) component inhalation powder ( e.g. , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion GP/ Investigator , contraindicate subject 's participation also exclude . 5 . Investigational Medications : A subject must use investigational drug within 30 day prior Visit 2 within five halflives ( t½ ) prior investigational study ( whichever longer two ) , ( unsure discus medical monitor prior screen ) 6 . Chronic user systemic corticosteroid : A subject , opinion GP/Investigator , consider chronic user systemic corticosteroid respiratory indication ( unsure discus medical monitor prior screen ) 7 . Subjects use LABA without ICS asthma maintenance therapy . 8 . Subjects plan move away geographical area study conduct study period and/or subject consent medical record part electronic medical record database operational Salford area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>respiratory</keyword>
	<keyword>adult</keyword>
	<keyword>asthma</keyword>
</DOC>